EUCTR2014-002217-31-FR进行中（未招募）不适用
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Subject is =18 years of age at the time of obtaining informed consent.
- •2) Subject is defined as morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the followings:
- •Refractory to at least 1 cycle of induction chemotherapy
- •Relapsed after achieving remission with a prior therapy
- •3) Subject has an Eastern Cooperative Oncology Group (ECOG) performance status =2.
- •4) Subject’s interval from prior treatment to time of study drug administration is at least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast cells), or at least 5 half-lives for prior experimental agents or noncytotoxic agents, including immunosuppressive therapy post hematopoietic stem cell transplantation (HSCT).
- •5) Subject must meet the following criteria as indicated on the clinical laboratory tests.
- •Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 x institutional upper limit normal (ULN)
- •Total serum bilirubin =1.5 x institutional ULN
- •Serum creatinine =1.5 x institutional ULN or an estimated glomerular filtration rate (eGFR) of > 50 ml/min as calculated by the Modification of Diet in Renal Disease (MDRD) equation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 115
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 115
排除标准
- •1. Subject was diagnosed as acute promyelocytic leukemia (APL).
- •2. Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
- •3. Subject has active malignant tumors other than AML or Myelodysplastic Syndrome (MDS).
- •4. Subject has persistent non-hematological toxicities of= Grade 2 (CTC AE v4), with symptoms and objective findings, from prior AML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery).
- •5. Subject has had hematopoietic stem cell transplant (HSCT) and meets any of the following:
- •Is within 2 months of transplant from C1D1
- •Has clinically significant graft-versus-host disease requiring treatment
- •Has = Grade 2 persistent non-hematological toxicity related to the transplant
- •Donor lymphocytes infusion (DLI) is not permitted = 30 days prior to study registration or during the first cycle of treatment on the study in Cohort 1 and first two cycles of the treatment in Cohort 2.
- •6. Subject has clinically active central nervous system leukemia.
- •7. Subject has disseminated intravascular coagulation abnormality (DIC).
- •8. Subject has had major surgery within 4 weeks prior to the first study dose.
- •9. Subject has had radiation therapy within 4 weeks prior to the first study dose.
- •10. Subject has congestive heart failure NYHA class 3 or 4, or subject with a history of congestive
- •heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram performed within
- •3 months prior to study entry results in a left ventricular ejection fraction that is = 45%.
- •11. Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of
- •CYP3A4 with the exception of antibiotics, antifungals, and antivirals that are used as standard of
- •care post-transplant or to prevent or treat infections and other such drugs that are considered
- •absolutely essential for the care of the subject.
- •12. Subject requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR
- •receptors or sigma nonspecific receptor with the exception of drugs that are considered absolutely
- •essential for the care of the subject.
研究者
相似试验
进行中（未招募）
1 期
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Acute Myeloid LeukemiaMedDRA version: 17.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-002217-31-ITAstellas Pharma Global Development, Inc.265
进行中（未招募）
1 期
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Acute Myeloid LeukemiaMedDRA version: 18.1 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864EUCTR2014-002217-31-DEAstellas Pharma Global Development, Inc.265
招募中
1 期
A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants with Duchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code: 10013801Term: Duchenne muscular dystrophy Class: 100000004850Duchenne Muscular DystrophyCTIS2023-506737-30-00Biomarin Pharmaceutical Inc.18
进行中（未招募）
1 期
A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors.--------------------------------------------------------Estudio abierto de fase 1b/2 con escalada de dosis de AMG 655 en combinación con AMG 479 en sujetos con tumores sólidos refractarios y avanzados.Part 1: Advanced, treatment-refractory solid tumorsPart 2: Advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, ovarian cancer, or sarcoma.------------------------------------------------------------Parte 1:tumores sólidos refractarios y avanzados.Parte 2:Cáncer de pulmón no microcítico avanzado (CPNM), cáncer colorrectal (CRC), cáncer pancreático, cáncer de ovario o sarcoma.MedDRA version: 9.1Level: LLTClassification code 10061451Term: Colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10033604Term: Pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerEUCTR2008-005074-12-ESAmgen Inc108
进行中（未招募）
1 期
A Phase 1/2 study to evaluate the safety and efficacy of BMN 307 gene therapy in patients with phenylketonuriaPhenylketonuriaEUCTR2019-001878-28-GBBioMarin Pharmaceutical Inc.100